Insitro was founded in 2018 and has raised $750 million from venture capital and pharma partnerships.
“Insitro was founded in 2018 and has secured $750 million in funding from venture capital firms and through partnerships with big drug makers”
Person
11 episodes · 30 quoted claims
Insitro was founded in 2018 and has raised $750 million from venture capital and pharma partnerships.
“Insitro was founded in 2018 and has secured $750 million in funding from venture capital firms and through partnerships with big drug makers”
Xaira Therapeutics debuted with $1 billion in committed capital in April 2024.
“It debuted with $1 billion in committed capital in April of 2024.”
Xaira Therapeutics was co-founded and incubated by Arch Venture Partners and Foresight Labs.
“Xaira was co-founded and incubated by Arch Venture Partners and Foresight Labs.”
David Baker won the 2024 Nobel Prize for work on computational protein design.
“Designing protein drugs on computers with ideal properties is a big idea that won Baker the Nobel Prize in 2024.”
David Baltimore won the Nobel Prize in 1975 at age 37 for his work on reverse transcriptase, according to host Luke Timmerman.
“He won the Nobel Prize in 1975 for that work at the age of 37.”
Baltimore was founding director of the Whitehead Institute for Biomedical Research, briefly president of Rockefeller University, and then president of Caltech.
“as the founding director of the Whitehead Institute for Biomedical Research, had a brief stint as president of Rockefeller University, and then served as president of Caltech”
Twenty of the scientists Baltimore mentored have been elected to the National Academy of Sciences, according to host Luke Timmerman.
“and 20 have been elected to the National Academy of Sciences.”
Luke Timmerman says his research for his Lee Hood book found that the average first-time R01 grant winner was about 30 in Hood's generation, versus early 40s now.
“I found that the average first time R01 grant winner when he was coming up was something like 30.”
Sue Desmond-Hellmann worked at Genentech from 1995 to 2009, a period the host describes as its glory days as a developer of cancer drugs.
“She made her name in the biopharmaceutical industry at Genentech from 1995 to 2009, the glory days when it became the world's most important developer of new cancer drugs.”
After leaving Genentech, Sue Desmond-Hellmann became Chancellor of UCSF and then CEO of the Bill and Melinda Gates Foundation until January 2020.
“After Genentech, she served as Chancellor of UCSF and then worked as CEO of the Bill and Melinda Gates Foundation until January of 2020.”
At the time of the interview, Desmond-Hellmann sat on Pfizer's board and advised the venture firm GV, formerly Google Ventures.
“Currently, among other things, Sue is a board member for Pfizer and is an advisor to GV, the venture capital firm formerly known as Google Ventures.”
Host Luke Timmerman credits Pfizer with helping BioNTech develop an mRNA COVID-19 vaccine in record time with very high efficacy.
“And I really want to give hats off to Pfizer for stepping up and helping BioNTech and developing this mRNA vaccine in record time and incredible efficacy.”
Herceptin was approved in 1998, about a year after Rituxan.
“And then Herceptin came just a year later, I think, 98.”
ARCH Venture Partners' Fund 11 is described by host Luke Timmerman as a $1.85 billion fund for investing in new biotech startups.
“Now for this conversation, I focus mainly on what Bob and the Arch investing team want to do with the latest fund, Fund 11. It's a $1.85 billion colossus to invest in new biotech startups.”
Bob Nelsen was an early investor in Illumina, Alnylam, Juno and Vir, according to Luke Timmerman.
“He was an early investor in gene sequencing technology with Illumina, RNA interference with alnylam, cell therapy with Juno, and infectious disease with Vir.”
Matthew Herper wrote a profile of Bob Nelsen for Forbes in 2016.
“Matt Herper wrote a nice profile of Bob for Forbes in 2016.”
Luke Timmerman began covering biotech at the Seattle Times, where he met Bob Nelsen early in Nelsen's time at ARCH.
“He was one of the first people I met when starting out covering biotech at the Seattle Times.”
ARCH's Fund 11 press release said it would still write investments ranging from $50,000 to $250 million.
“But you mentioned that you're still going to do these $50 ,000 checks all the way up to $250 million, whatever the thing requires.”
Luke Timmerman says the Fund 11 press release lists infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic and biological tools, and data sciences among its areas.
“Infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic, biological tools, data sciences.”
insitro raised a $143 million Series B financing in May 2020, led by Andreessen Horowitz.
“as it raised a $143 million Series B financing in May 2020, led by Andreessen Horowitz, and which included earlier investors like ArchVenture Partners, Foresight Capital, GV, and Third Rock Ventures.”
Roche acquired Flatiron Health in February for $2.1 billion, according to host Luke Timmerman.
“Flatiron was acquired by Roche in February for $2.1 billion.”
Luke Timmerman notes that Merck launched Gardasil and Pfizer-Wyeth launched Prevnar, two commercially successful vaccines, before Clark joined Genocea.
“Merck had come out with Gardasil and Pfizer-Wyeth had come out with Prevnar.”
Genocea shelved its genital herpes vaccine program in September 2017, according to host Luke Timmerman, with Clark agreeing.
“You end up deciding to put the herpes program on the shelf September of last year, 2017.”
Luke Timmerman says Genocea had about $12 million in cash at the end of 2017 while spending roughly $50 million a year.
“I saw you were down to about 12 million cash at the end of 2017. So when you're burning 50 million a year, you don't have to be a math genius.”
Luke Timmerman says Genocea raised about $55 million in January 2018.
“So this is all preclinical. I know you raised another about 55 million, I think, in January.”
Host Luke Timmerman says Moderna Therapeutics attracted about $2 billion from investors and partners over eight years, much of it before human data.
“Moderna has been able to convince enough investors and partners to throw $2 billion behind its efforts over the last eight years to create this new modality of treatment.”
Luke Timmerman says Moderna's deal with AstraZeneca included $240 million up front for mRNA drugs across about 40 indications.
“AstraZeneca, $240 million up front to develop mRNAs against something like 40 different indications, cardiovascular, metabolic, and a couple of other things.”
Zerhouni joined Sanofi as head of R&D in 2011, according to host Luke Timmerman.
“He took his current job at Sanofi in 2011.”
As of the interview, Regeneron Pharmaceuticals had six FDA-approved drugs and was described as the third best-performing stock in the S&P 500 over the prior decade.
“The company has developed six FDA-approved drugs so far, and it's the third best-performing stock in the S &P 500 over the past decade.”
Luke Timmerman said Allergan transferred patents to an Indian tribe with sovereign immunity to prevent generic companies from challenging them in court, to protect a dry eye franchise.
“Allergan comes out with this patent gambit where they transferred over to an Indian tribe with sovereign immunity so that generic companies can't challenge their patents in court.”